Time for united action on depression: a Lancet–World Psychiatric Association Commission

H Herrman, V Patel, C Kieling, M Berk, C Buchweitz… - The Lancet, 2022 - thelancet.com
Executive summary “Depression is a disorder of mood, so mysteriously painful and elusive
in the way it becomes known to the self—to the mediating intellect—as to verge close to …

Blinding and expectancy confounds in psychedelic randomized controlled trials

SD Muthukumaraswamy, A Forsyth… - Expert review of clinical …, 2021 - Taylor & Francis
Introduction: There is increasing interest in the potential for psychedelic drugs such as
psilocybin, LSD and ketamine to treat several mental health disorders, with a growing …

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network …

A Cipriani, TA Furukawa, G Salanti, A Chaimani… - The Lancet, 2018 - thelancet.com
Background Major depressive disorder is one of the most common, burdensome, and costly
psychiatric disorders worldwide in adults. Pharmacological and non-pharmacological …

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

F Palhano-Fontes, D Barreto, H Onias… - Psychological …, 2019 - cambridge.org
BackgroundRecent open-label trials show that psychedelics, such as ayahuasca, hold
promise as fast-onset antidepressants in treatment-resistant depression. MethodsTo test the …

Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network …

J Mutz, V Vipulananthan, B Carter, R Hurlemann… - bmj, 2019 - bmj.com
Objective To estimate the comparative clinical efficacy and acceptability of non-surgical
brain stimulation for the acute treatment of major depressive episodes in adults. Design …

Treatment outcomes for depression: challenges and opportunities

P Cuijpers, A Stringaris, M Wolpert - The Lancet Psychiatry, 2020 - thelancet.com
Depressive disorders are common, costly, have a strong effect on quality of life, and are
associated with considerable morbidity and mortality. Effective treatments are available …

Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential …

JC Jakobsen, KK Katakam, A Schou, SG Hellmuth… - BMC psychiatry, 2017 - Springer
Background The evidence on selective serotonin reuptake inhibitors (SSRIs) for major
depressive disorder is unclear. Methods Our objective was to conduct a systematic review …

Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany …

G Burkhardt, U Kumpf, A Crispin, S Goerigk, E Andre… - The Lancet, 2023 - thelancet.com
Background Transcranial direct current stimulation (tDCS) has been proposed as a feasible
treatment for major depressive disorder (MDD). However, meta-analytic evidence is …

Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis

BDM Jones, LB Razza, CR Weissman, J Karbi… - JAMA network …, 2021 - jamanetwork.com
Importance The placebo effect in depression clinical trials is a substantial factor associated
with failure to establish efficacy of novel and repurposed treatments. However, the …

Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews

G Gartlehner, G Wagner, N Matyas, V Titscher… - BMJ open, 2017 - bmjopen.bmj.com
Objectives This study aims to summarise the evidence on more than 140 pharmacological
and non-pharmacological treatment options for major depressive disorder (MDD) and to …